ICER

What ICER does

ICER (Institute for Clinical and Economic Review), legally "Evidence for Healthcare Improvement," is an independent, non-partisan 501(c)(3) non-profit research organization founded in 2006 by Dr. Steven D. Pearson at Harvard Medical School/Massachusetts General Hospital and spun out as a standalone entity in 2013. Headquartered in Boston with 11-50 employees (approximately 35 named staff across research, health economics, and operations), ICER conducts evidence-based reviews of prescription drugs, medical tests, devices, and healthcare delivery innovations, producing public reports that quantify comparative clinical effectiveness and cost-effectiveness using its proprietary Value Assessment Framework and QALY/evLYG metrics. Its outputs include Health Benefit Price Benchmarks (fair-price ranges aligned to clinical benefit), the Clinical Trial Diversity Rating Tool, policy papers, and special assessments for the CMS Medicare Drug Price Negotiation program, with deliberation handled by three independent regional appraisal committees (CTAF, Midwest CEPAC, New England CEPAC).

ICER's product surface spans free public reports (downloaded as PDFs from icer.org), the subscription-based ICER Analytics cloud platform for payers and life science companies, ICER Scientific Advice for manufacturers, and policy papers on accelerated approval and drug pricing reform. The organization is funded primarily by non-profit foundation grants (notably a transformational Arnold Ventures grant during 2014-2016), individual donations, Policy Leadership Forum dues from life science companies and payers (capped at <25% of annual revenue), and ICER Analytics subscriptions. It serves US public and private payers (state Medicaid agencies, VA, 75%+ of private insurers and PBMs, employer coalitions), pharmaceutical manufacturers, patient advocacy groups, clinical experts, and federal and state policymakers, with documented adoption by UnitedHealthcare, Aetna, Kaiser Permanente, Blue Cross Blue Shield of MA, Harvard Pilgrim, Express Scripts, and New York Medicaid.

The business model is a freemium hybrid: free public reports drive awareness and institutional credibility while a paid analytics layer, manufacturer advisory service, and capped industry forum dues monetize enterprise use. Distribution is fully digital—website, weekly newsletter, podcast, social channels, and 3-4 public committee meetings per year—and the organization deliberately maintains independence through its funding-source restrictions and conflict-of-interest policies. As of 2025-2026, ICER is expanding into annual launch-price market surveillance, CMS price-negotiation support, and FDA regulatory pathway reform, indicating a strategic shift from episodic drug assessments toward continuous market and policy intelligence.

Name

ICER

Legal name

Evidence for Healthcare Improvement

Website

https://icer.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

ICER is an independent Boston-based non-profit research organization that conducts evidence-based reviews of drugs and medical devices, producing Health Benefit Price Benchmarks and value assessments used by 75%+ of US private insurers, PBMs, state Medicaid agencies, and the VA to inform formulary and pricing decisions.

Ownership category

akta.pro rank

Product category

Health Technology Assessment

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health Technology Assessment (HTA) & Reimbursement Policy Bodies (HLAJACAF)

akta.pro secondary industries

Economic Evaluation & Health Technology Assessment (Public Programs) (HLAJANAL), Payer & HTA Engagement (Reimbursement/Submissions) (HLAIAKAD)

Keywords

• Health technology assessment
• Clinical effectiveness research
• Pharmaceutical pricing analysis
• Value-based pricing benchmarks
• Drug cost-effectiveness analysis

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Foundation Grants: ICER is primarily funded by grants from non-profit foundations including the Laura and John Arnold Foundation (now Arnold Ventures) which provided a transformational financial grant enabling expansion of ICER's work.
2. Donations: As a 501(c)(3) non-profit, ICER accepts donations from individuals. All donations are tax-deductible to the extent allowed by law.
3. Policy Leadership Forum Dues: Life science companies and commercial payers participate in ICER's Policy Leadership Forum, with dues contributing to ICER's annual Policy Summit. These contributions represent less than 25% of annual revenue.
4. ICER Analytics Subscriptions: ICER Analytics is a subscription-based cloud platform that enables frequent users of ICER's work to customize and implement findings. This represents a commercial revenue stream for the organization.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

ICER conducts independent, evidence-based reviews of prescription drugs, medical tests, devices, and health system delivery innovations, producing clinical and economic value assessments together with Health Benefit Price Benchmarks (HBPBs) that suggest fair price ranges. It monetizes this research through the ICER Analytics subscription platform (customizable implementation of findings for payers, life science companies, and policymakers) and the ICER Scientific Advice service (paid advisory for manufacturers on how their therapies will be evaluated).

Product overview

ICER is an independent, non-profit research institute that conducts evidence-based reviews of healthcare interventions. The organization operates as a platform-based model centered on its core ICER Evidence Reports, supplemented by the ICER Analytics subscription platform for customized analysis implementation, and the ICER Scientific Advice service for manufacturer engagement. Key methodology tools include the Value Assessment Framework (using QALY and evLYG metrics), Health Benefit Price Benchmarks, and the Clinical Trial Diversity Rating Tool. ICER also produces Policy Papers addressing healthcare system issues and Special Assessments for CMS drug price negotiations. The organization engages patients through its Patient Portal and maintains public deliberation processes through three independent appraisal committees (CTAF, Midwest CEPAC, New England CEPAC).

Differentiator

Problem solved

Functional benefit

Brands

• ICER Analytics™: A subscription-based cloud platform that enables payers, life science companies, patient groups, and others to customize and implement ICER findings for formulary development, drug price negotiations, and evidence application
• ICER Scientific Advice

Products and services

• ICER Evidence Reports Evidence-based reviews of prescription drugs, medical tests, devices, and health system delivery innovations that measure clinical and economic value and suggest fair prices via the Health Benefit Price Benchmark. Produced for payers, life science companies, policymakers, and patient groups, and made publicly available as free downloadable PDFs.
• ICER Analytics Platform Subscription-based cloud platform that enables payers, life science companies, patient groups, and policymakers to customize and implement ICER's findings in formulary decisions, drug price negotiations, and evidence-based coverage decisions.
• ICER Scientific Advice Advisory service that helps pharmaceutical and life science manufacturers understand ICER's assessment methodology and how their therapies may be evaluated for clinical and economic value and pricing.
• Policy Papers Standalone analyses on healthcare policy issues including unsupported price increases, fair access coverage, gene therapy payment challenges, and evaluations of FDA regulatory pathways.
• Special Assessments for CMS Drug Price Negotiation Special reports developed for the Centers for Medicare & Medicaid Services to inform Medicare Drug Price Negotiation, covering selected drugs (e.g., vedolizumab/Entyvio) for specified price applicability years.

Quantifiable outcome

• New York Medicaid saved nearly $500 million since 2018 using ICER reports to negotiate supplemental rebates on approximately 50 drugs
• +3 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• AetioncoreTechnology or Integration · 1 January 2020ICER and Aetion announced a partnership and platform to generate decision-grade real-world evidence (RWE). This partnership was launched in 2020 to set new standards for how RWE can inform pharmaceutical pricing and patient access decisions.
• IPD AnalyticscoreStrategic or Co-development PartnerICER collaborates with IPD Analytics, an independent organization that performs analyses of the emerging drug pipeline for diverse industry stakeholders including payers, manufacturers, providers, and wholesalers. IPD provides tailored reports on the drug pipeline to ICER on a courtesy basis.
• National Health CouncilminorStrategic or Co-development PartnerICER collaborated with the National Health Council to conduct facilitated group discussions with patient groups for the Launch Price and Access Report.
• Policy Leadership Forum MembersminorStrategic or Co-development PartnerLife science companies and commercial payers participate in ICER's Policy Leadership Forum, contributing dues to ICER's annual Policy Summit. Contributions represent less than 25% of ICER's annual revenue. The forum convenes leaders from both industries to discuss initiatives for fair pricing and fair access.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Aetion: Health economics and outcomes research technology partner that produces decision-grade real-world evidence for payers and life sciences. Listed as a strategic ICER partner for RWE generation, and competes for the same RWE/biotech budget with a more technology-focused SaaS model — explicitly comparable as the enabling technology layer in pharma value-and-access decisions.
• Drug Pricing Lab (Memorial Sloan Kettering): Independent academic initiative publishing evidence on US drug pricing and value-based policy alternatives. Comparable mission and audience (policymakers, payers, patient groups), though narrower scope and smaller analytical output than ICER — a thematic competitor for policy influence.

Broad incumbents

• Canadian Agency for Drugs and Technologies in Health (CADTH): Canadian federal/provincial HTA agency that conducts comparative clinical and cost-effectiveness reviews used by public payers for formulary and pricing decisions. Directly comparable to ICER on mandate, methodology (QALY/ICER-style frameworks), and customer base (public payers + life sciences), with the same independence positioning.
• National Institute for Health and Care Excellence (NICE): UK government-arm's-length HTA body that issues cost-effectiveness/QALY-based guidance used by the NHS to determine reimbursement and access. The closest functional analogue to ICER's role in the US, with overlapping methodology (QALY-based health economic evaluation) and parallel payer/government buyer set.
• Institute for Quality and Efficiency in Health Care (IQWiG): Germany's independent HTA agency that conducts evidence-based benefit assessments of medical interventions to inform GKV-Spitzenverband pricing decisions. Comparable to ICER in its independent HTA stance, methodology rigor, and role feeding payer reimbursement decisions, though QALY use has been politically constrained by German law.

Direct peers

• ECRI Institute: Independent, non-profit health technology evaluation organization providing evidence-based assessments, comparative effectiveness research, and patient safety guidance to payers, providers, and government. Overlapping mission with ICER and similar institutional B2B buyer profile, with broader medical device/diagnostic scope.
• Tufts Center for the Evaluation of Value and Risk (CEVR): US-based academic HTA research center publishing cost-effectiveness analyses and the Specialty Drug Evidence and Coverage (SPEC) database. Direct peer on methodology and topic coverage, and confirmed as an ICER data partner on the Launch Price and Access Report — explicitly comparable on scientific approach and US payer relevance.
• Hayes, Inc. (a TractManager Company): Subsidiary of TractManager providing subscription-based health technology assessments, clinical evidence reviews, and payer-facing evidence reports for medical devices, drugs and diagnostics. Comparable subscription/HTA business model and payer-buyer profile, with greater focus on devices and diagnostics and a commercial (paid) B2B model rather than non-profit.

Regional players

• Oregon Health Authority Health Evidence Review Commission: State-level HTA body that uses comparative effectiveness and cost-effectiveness methods (including QALY/HBHB analogues) to prioritize Medicaid coverage on Oregon's Prioritized List. Functionally similar HTA methodology as ICER but geographically narrower (single state Medicaid buyer) and smaller scale.

Others

• Blue Cross Blue Shield Association Evidence Street / Center for Clinical Effectiveness: BCBSA's internal evidence-based program that produces technology assessments and drug reviews to inform Blue plan coverage decisions. Comparable as a payer-affiliated HTA consumer of ICER outputs, with overlapping methodology and coverage in formulary decisioning, though internally focused on BCBSA plans rather than independent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/icer_review
• LinkedInlinkedin.com/company/institute-for-clinical-and-economic-review
• Instagraminstagram.com/icer_review

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICER